These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12510397)

  • 41. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential boundaries approach in clinical trials with unequal allocation ratios.
    Jafari P; Ayatollahi SM; Behboodian J
    BMC Med Res Methodol; 2006 Jan; 6():1. PubMed ID: 16412232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
    Thorlund K; Devereaux PJ; Wetterslev J; Guyatt G; Ioannidis JP; Thabane L; Gluud LL; Als-Nielsen B; Gluud C
    Int J Epidemiol; 2009 Feb; 38(1):276-86. PubMed ID: 18824467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Roaming through methodology. XXXIII. Ethics of sample size estimation: less subjects needed for a one-sided than for a two-sided statistical investigation].
    Knottnerus JA; Bouter LM
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1051-4. PubMed ID: 11414165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How much do we have to pay for how many interim analyses?
    Koch A
    Contemp Clin Trials; 2005 Feb; 26(1):113-6. PubMed ID: 15837456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses.
    Brok J; Thorlund K; Wetterslev J; Gluud C
    Int J Epidemiol; 2009 Feb; 38(1):287-98. PubMed ID: 18824466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.
    Wetterslev J; Thorlund K; Brok J; Gluud C
    J Clin Epidemiol; 2008 Jan; 61(1):64-75. PubMed ID: 18083463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adaptive group sequential test with changing patient population.
    Feng H; Liu Q
    J Biopharm Stat; 2012; 22(4):662-78. PubMed ID: 22651107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A flexible strategy for testing subgroups and overall population.
    Alosh M; Huque MF
    Stat Med; 2009 Jan; 28(1):3-23. PubMed ID: 18985704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential analysis of latent variables using mixed-effect latent variable models: Impact of non-informative and informative missing data.
    Sébille V; Hardouin JB; Mesbah M
    Stat Med; 2007 Nov; 26(27):4889-904. PubMed ID: 17576119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Interim analysis in therapeutic trials: a brief survey of current developments].
    Falissard B; Lellouch J
    Rev Epidemiol Sante Publique; 1991; 39(4):365-72. PubMed ID: 1754702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On the sequential design of the Deutsche Nikotinamid Interventionsstudie--DENIS.
    Haastert B; Giani G
    Diabete Metab; 1993; 19(1 Pt 2):100-4. PubMed ID: 8314410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A note on P-values under group sequential testing and nonproportional hazards.
    Gillen DL; Emerson SS
    Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T; Kieser M
    Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.